BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19830389)

  • 1. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
    Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
    Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
    Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
    Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
    Kudchadkar R; Ernst S; Chmielowski B; Redman BG; Steinberg J; Keating A; Jie F; Chen C; Gonzalez R; Weber J
    Cancer Med; 2015 May; 4(5):643-50. PubMed ID: 25533314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
    Cheson BD; Bartlett NL; Vose JM; Lopez-Hernandez A; Seiz AL; Keating AT; Shamsili S; Papadopoulos KP
    Cancer; 2012 Jun; 118(12):3128-34. PubMed ID: 22006123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
    Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
    J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
    Tolcher AW; Quinn DI; Ferrari A; Ahmann F; Giaccone G; Drake T; Keating A; de Bono JS
    Ann Oncol; 2012 Apr; 23(4):968-73. PubMed ID: 21859898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
    Aoyama Y; Kaibara A; Takada A; Nishimura T; Katashima M; Sawamoto T
    Invest New Drugs; 2013 Apr; 31(2):443-51. PubMed ID: 22892872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
    Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
    Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
    Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.
    Fujita M; High WA; Asgari S; Lewis KD; Gonzalez R
    Int J Dermatol; 2009 Apr; 48(4):426-30. PubMed ID: 19335434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
    Minematsu T; Iwai M; Sugimoto K; Shirai N; Nakahara T; Usui T; Kamimura H
    Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.